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C O N T I N U E D
How effective is prophylactic
therapy for gout in people
with prior attacks? 
■ EVIDENCE-BASED ANSWER
Colchicine (strength of recommendation [SOR]:
B, based on 1 double-blind crossover study),
allopurinol (SOR: B, based on 2 cohort studies),
and weight loss (SOR: B, based on 1 small
cohort study) have been shown to reduce symp-
tomatic recurrences of gout, although the data
to support their use is limited. Some evidence
suggests that despite their serum uric acid–low-
ering effects, uricosurics (such as probenecid)
fail to reduce gout attacks (SOR: B, based on 2
cohort studies). We were unable to find any dou-
ble-blind, placebo-controlled long-term outcome
studies addressing this problem. 
■ EVIDENCE SUMMARY
The majority of gout sufferers are uric acid
undersecretors rather than overproducers; how-
ever, many patients will have a combination of
these 2 processes, as well as caloric or purine
overindulgence. Efforts to limit the frequency
and intensity of gout attacks have focused on
reducing the uric acid load or reducing the
inflammatory response to intra-articular crystal
deposition. Pharmacologic therapies include 1)
uricosurics, such as probenecid, sulfinpyrazone
and benzbromarone (used mostly in Europe),
which increase the renal clearance of uric acid,
2) xanthine oxidase inhibitors such as allopuri-
nol, which limit the formation of uric acid to
yield a more water soluble chemical, and 3) anti-
inflammatory medications, including nons-
teroidal anti-inflammatory drugs (NSAIDs) and
colchicine. Obesity and insulin resistance are
associated with elevated uric acid, suggesting
that weight loss may also help reduce episodes
of gout. 
A double-blinded crossover study of 38 veter-
an men with recurrent gout found that the addi-
tion of daily colchicine to uricosurics reduced
the frequency of attacks by nearly two thirds in
6 months of follow-up.1 A cohort study of 208
men with confirmed gout who used either daily
colchicine alone or colchicine with uricosurics
for 2 to 10 years found marked improvements in
attack frequency in both groups, yet there was
no difference between the intervention groups.2
An additional study followed 734 patients
(including some of the subjects in the first
cohort study) and reported similar outcomes.3
Allopurinol was studied in 46 patients using
prophylactic colchicine with an average follow-
up of 12 months.4 Attack rates were unchanged
for the first several weeks followed by a decline
in the attack rate and a regression of tophi.
When allopurinol was added to uricosurics in
48 patients, tophi were reduced.5
An average weight loss of 7.7 kg had a ben-
eficial effect on serum uric acid levels and gout
attack rates in 13 nondiabetic men, who were
placed on a carefully controlled 1600-calorie
diet with 40% of calories from complex carbo-
hydrates.6
In a small study, the addition of uricosurics
did not reduce the gout attack rate in 14
patients with nontophaceous gout.7 Patients
were followed over 12 to 15 months in a
crossover study of colchicine and placebo ver-
sus colchicine and sulfinpyrazone. Although
this study had limited power, a larger cohort
study had similar findings over a longer 
follow-up period.3
We were unable to find any applicable stud-
ies of daily NSAID use, dietary purine control,
or alcohol reduction for the secondary preven-
tion of gout. A prospective study of primary
gout involving 47,150 men followed over 12
years noted a relative risk (RR) of gout 1.41
(95% confidence interval [CI], 1.07–1.86) in the
highest quintile of meat eaters, a RR of 1.51
(95% CI, 1.17–1.95) in the highest quintile of
seafood eaters, and an inverse relationship of
dairy intake with gout risk.8 Thiazide diuretics
appear to increase the likelihood of a gout diag-
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nosis and if used, could be discontinued,
although no studies have investigated this inter-
vention. Most of the gout studies were per-
formed in the 1960s using simple cohort designs
and limited statistical analysis; some used com-
binations of medications and variable dosing.
Only allopurinol appears effective in resorbing
tophi5 and may have greater utility for patients
with severe tophaceous gout, in those intolerant
to uricosurics, in gross overproduction of uric
acid, for patients with uric acid stones, or for
those with renal impairment. 
■ RECOMMENDATIONS FROM OTHERS
An expert panel, recruited by the Agency for
Healthcare Research and Quality, recently pub-
lished a summary combining evidence and
expert opinion, which suggested that colchicine
is a good prophylactic therapy and that uric acid
lowering drugs (allopurinol, probenecid, and
sulfinpyrazone) are effective in decreasing
attack frequency in those with more than 2
attacks per year.9 Weight loss and alcohol reduc-
tion were also encouraged. A Cochrane review
of this topic is scheduled for completion in 2004. 
Vincent J. WinklerPrins, MD, Arlene M. Weismantel,
MILS, Michigan State University, East Lansing
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■ CLINICAL COMMENTARY
Prophylactic therapy is recommended 
for frequent attacks
Long-term therapy is recommended when fre-
quent gouty attacks occur. Care is warranted in
the use of colchicine with erythromycin, sim-
vastatin, and cyclosporine, since these drugs
modify the excretion of colchicine, which may
lead to toxic doses.10 Uric acid–lowering
agents, such as allopurinol and probenecid,
should be avoided in acute attacks of gout, due
to potential worsening of inflammation.
Nonadherence with long-term prophylac-
tic therapy for gout can lead to acute attacks,
but patients who adhere to prophylactic thera-
py can still experience occasional acute break-
throughs of gout. The Cochrane review in
progress may shed more insight into the pre-
vention of acute gouty inflammation..
Thuy Hanh Trinh, MD, Baylor College of Medicine,
Houston, Tex
Does tight control of blood
glucose in pregnant women
with diabetes improve
neonatal outcomes?
■ EVIDENCE-BASED ANSWER
In pregnant women with preexisting type 1 dia-
betes mellitus, maintaining near-normal blood
glucose levels decreases the rate of major con-
genital anomalies (defined as those causing
death or a serious handicap necessitating surgi-
cal correction or medical treatment). Prolonged 
preconception control of blood sugar to near-
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